Onco Actu du 20 juin 2016

	2.7 Etiologie - Obésité
Being obese or overweight could cause 7.6 million cases of disease by 2035 [Cancer Research UK] These numbers are shocking. And it’s difficult to think of the impact this will have on public health and an already strained NHS. Without bold action, the next generation will face more disease and live shorter lives.
56,000 Britons a year will develop cancer because they are too fat, shocking report warns [The Telegraph] An extra 7.6 million cases of disease linked to being overweight or obese will be diagnosed in the UK over the next 20 years - including 670,000 new cases of cancer - according to new figures from the Obesity Health Alliance.
	3.3 Prévention - Vaccins
Cancer doctors leading campaign to boost use of HPV vaccine [Washington Post] “Pediatricians never see the cancers caused by HPV, so some of them don’t recognize the vaccine’s importance in preventing cancer,” she said. “They don’t know how to talk about it with patients, or they wait too long. And their knowledge level is not where it should be.”
	3.8 Prévention - Alimentation
Could 5:2 diet play a role in preventing breast cancer? [NHS Choices] The study sample was small, and definitely not large enough to be able to make solid statements about breast cancer in general. As the causes of breast cancer aren't fully understood, it's not known if it can be prevented altogether.
	5.10 Traitements - Essais
Whither the randomized controlled clinical trial? [Science-Based Medicine] Then, of course, there’s the development of “precision” medicine (formerly known as “personalized” medicine), which involves using various genomic markers and other biomarkers from individual patients to determine which treatment should be used. On the surface, this appears to be a major challenge to RCTs, but I’ve come to think that the challenge, while formidable, is perhaps not so insurmountable as critics of RCTs would like you to think.
	5.12 Immunothérapies
Combination immunotherapy treatment for melanoma given NHS approval [Cancer Research UK] “These results give new hope to melanoma patients. But, it’s important to remember that more powerful treatment comes with an increased chance of severe side effects,” he said.
Speedy approval for melanoma drug combination [PHG Foundation] The two drugs have an extensive list of side-effects but NICE concluded that those effects, whilst severe did not outweigh the positives, but the toxicity of the treatment meant it was a "promising new advance" only for those patients strong enough to withstand the side-effects.
Merck's Edge on Bristol-Myers Won't Last [Bloomberg] This IO race contrasts two competing approaches to drug development: tightly focused trials, which bolster the likelihood of success in a given treatment, versus broader trials that get a drug to as many patients as possible but have a greater risk of failure because they are less picky.
Keytruda (Pembrolizumab) Beats Chemo as First Line Therapy for Patients with High Tumor Expression of PD-L1: Where are We Now? [GRACE] This trial marks the first clear evidence of a value in testing for PD-L1 in advanced NSCLC.
	5.2 Pharma
Epizyme Touts Early Data From Key Trial Of Blood Cancer Drug [Xconomy] In essence, the trial is not even one-third complete. Epizyme has only enrolled 82 of the planned 270 patients, and only a handful of them have been treated for more than five months.
	5.8 ASH
American Society of Hematology to Host Scientific Meeting on Breakthroughs in Lymphoma Biology  [ASH] More than 300 lymphoma experts from around the world will attend the meeting to share cutting-edge research and focus on key priorities to accelerate the development of new approaches to understanding and treating lymphoma.
	6. Lutte contre les cancers
Cancer Survivorship Conference Highlights Changes in Survivor Care and Service Delivery [ACS] Since 2002, the Biennial Cancer Survivorship Research Conference has brought together investigators, clinicians, advocates, cancer survivors, program planners, policy-makers, and public health experts to highlight cancer survivorship research and to advance progress in survivorship care.
	6.10 Politiques
Philanthropist Bill Gates talks public health, biotech, and the race for the White House [STAT] What do you think of Vice President Biden’s “moonshot“? Anything that gets us more money for medical research is a good thing. I don’t know about that construct specifically. There’s always a tendency in the slogans we use in health to potentially overpromise. But people need to get excited. We had the war on cancer, you know cancer has won several rounds of that war …
	6.6 Publications
How do we read research papers? [Academy Health Blog] One thing I never do, though, is read press releases. I make it a point not to discuss papers I haven’t read myself.
	6.7 DMP, Big Data & applis
Why there will never be an Uber for healthcare [Tech Crunch] Healthcare is not a transaction business; it is a relationship business. One cannot “get healthy” with a one-time, immediate transaction. Instead, positive health outcomes are achieved over a long time period through a treatment plan developed in conjunction with a trained physician with whom a patient has a strong relationship.
	6.9 Controverses
Personalised medicine has obvious benefits but has anyone thought about the issues? [The Conversation] The hope is that precision medicine will eventually enable more cost-effective care. Yet easy access to genetic testing could create a growing class of the “worried well” – people afraid their genetic makeup is a ticking time-bomb for future disease.